Research library
Longevity/peptide

SS-31 / Elamipretide

Canonical identity: Elamipretide

Also indexed as: MTP-131 · Bendavia · SS-31

A mitochondria-targeted peptide studied in preclinical and clinical research.

Evidence level

Human research, limited or context-specific

Verified against the linked source set on 2026-08-20.

What it is

Elamipretide, also known as SS-31 or MTP-131, is a mitochondria-targeted tetrapeptide studied in mitochondrial bioenergetics and tissue-response research.

Mechanism and research questions

  • Research focuses on interactions with mitochondrial inner-membrane components and cardiolipin-associated function.
  • Studies examine effects on mitochondrial bioenergetics rather than a general anti-aging claim.

Human evidence

Human studies have investigated specific diseases and endpoints; results must be read study by study rather than generalized.

Preclinical / mechanistic evidence

Cell and animal studies examine mitochondrial function, oxidative stress, and tissue recovery.

Evidence summary

There is a clinical research program and a substantial mechanistic literature, but this does not establish an approved use for catalog material.

Limits and interpretation

  • Evidence is indication-specific and not a universal longevity claim.
  • Clinical development status can change; verify current trial records.
  • Research-vial identity and formulation are separate from trial-grade material.

Regulatory and identity note

Investigational research compound in the reviewed context.

Research summaries reflect primary literature, patent landscapes, and regulatory status reports at the time of review. They do not constitute therapeutic advice, endorsement, or claims regarding unauthorized preparations.